Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M – CDC

by

  1. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M CDC
  2. RSV shot for infants 90 percent effective against hospitalizations: CDC The Hill
  3. CDC says new treatment for infant RSV infections ‘highly effective’ in preventing hospitalization WSB Atlanta
  4. Only nine percent of older Americans were vaccinated against RSV before the disease hit this fall and winter Medical Xpress
  5. RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC STAT

Read original article here

Leave a Comment